Which has preferable earnings & valuation, MEDP or EHC?

Encompass Health has higher revenue and earnings than Medpace. Encompass Health is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Medpace $2.53B 5.05 $451.12M $15.91 28.10 Encompass Health $5.94B 1.77 $566.20M $5.99 17.69

Does the media favor MEDP or EHC?

In the previous week, Medpace had 22 more articles in the media than Encompass Health. MarketBeat recorded 31 mentions for Medpace and 9 mentions for Encompass Health. Encompass Health's average media sentiment score of 1.37 beat Medpace's score of 0.28 indicating that Encompass Health is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Medpace 5 Very Positive mention(s) 1 Positive mention(s) 24 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Encompass Health 8 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation & earnings, MEDP or ELV?

Elevance Health has higher revenue and earnings than Medpace. Elevance Health is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Medpace $2.53B 5.05 $451.12M $15.91 28.10 Elevance Health $199.13B 0.43 $5.66B $23.51 16.78

Is MEDP or ELV more profitable?

Medpace has a net margin of 17.19% compared to Elevance Health's net margin of 2.62%. Medpace's return on equity of 120.89% beat Elevance Health's return on equity. Company Net Margins Return on Equity Return on Assets Medpace 17.19% 120.89% 24.79% Elevance Health 2.62% 15.58% 5.57%

Does the media refer more to MEDP or ELV?

In the previous week, Medpace had 19 more articles in the media than Elevance Health. MarketBeat recorded 31 mentions for Medpace and 12 mentions for Elevance Health. Elevance Health's average media sentiment score of 1.39 beat Medpace's score of 0.28 indicating that Elevance Health is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Medpace 5 Very Positive mention(s) 1 Positive mention(s) 24 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Elevance Health 10 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings and valuation, MEDP or HIMS?

Medpace has higher revenue and earnings than Hims & Hers Health. Hims & Hers Health is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Medpace $2.53B 5.05 $451.12M $15.91 28.10 Hims & Hers Health $2.35B 2.58 $128.37M -$0.09 N/A

Does the media refer more to MEDP or HIMS?

In the previous week, Medpace had 9 more articles in the media than Hims & Hers Health. MarketBeat recorded 31 mentions for Medpace and 22 mentions for Hims & Hers Health. Hims & Hers Health's average media sentiment score of 0.57 beat Medpace's score of 0.28 indicating that Hims & Hers Health is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Medpace 5 Very Positive mention(s) 1 Positive mention(s) 24 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Hims & Hers Health 9 Very Positive mention(s) 4 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 2 Very Negative mention(s) Positive

Which has preferable valuation and earnings, MEDP or IQV?

IQVIA has higher revenue and earnings than Medpace. IQVIA is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Medpace $2.53B 5.05 $451.12M $15.91 28.10 IQVIA $16.31B 1.86 $1.36B $8.07 22.56

Is MEDP or IQV more profitable?

Medpace has a net margin of 17.19% compared to IQVIA's net margin of 8.33%. Medpace's return on equity of 120.89% beat IQVIA's return on equity. Company Net Margins Return on Equity Return on Assets Medpace 17.19% 120.89% 24.79% IQVIA 8.33% 30.50% 6.53%

Does the media refer more to MEDP or IQV?

In the previous week, Medpace had 24 more articles in the media than IQVIA. MarketBeat recorded 31 mentions for Medpace and 7 mentions for IQVIA. IQVIA's average media sentiment score of 0.40 beat Medpace's score of 0.28 indicating that IQVIA is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Medpace 5 Very Positive mention(s) 1 Positive mention(s) 24 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral IQVIA 1 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger earnings & valuation, MEDP or WCN?

Waste Connections has higher revenue and earnings than Medpace. Medpace is trading at a lower price-to-earnings ratio than Waste Connections, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Medpace $2.53B 5.05 $451.12M $15.91 28.10 Waste Connections $9.47B 4.02 $1.08B $4.10 36.37

Is MEDP or WCN more profitable?

Medpace has a net margin of 17.19% compared to Waste Connections' net margin of 10.97%. Medpace's return on equity of 120.89% beat Waste Connections' return on equity. Company Net Margins Return on Equity Return on Assets Medpace 17.19% 120.89% 24.79% Waste Connections 10.97% 16.49% 6.45%

Does the media refer more to MEDP or WCN?

In the previous week, Medpace had 24 more articles in the media than Waste Connections. MarketBeat recorded 31 mentions for Medpace and 7 mentions for Waste Connections. Waste Connections' average media sentiment score of 1.30 beat Medpace's score of 0.28 indicating that Waste Connections is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Medpace 5 Very Positive mention(s) 1 Positive mention(s) 24 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Waste Connections 6 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Medpace (MEDP) Competitors

$447.11 -1.01 (-0.23%)

Closing price 05/29/2026 04:00 PM Eastern

Extended Trading

$443.33 -3.78 (-0.85%)

As of 05/29/2026 07:59 PM Eastern

Compare

MEDP vs. EHC, ELV, HIMS, IQV, and WCN

Should you buy Medpace stock or one of its competitors? MarketBeat compares Medpace with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Medpace include Encompass Health (EHC), Elevance Health (ELV), Hims & Hers Health (HIMS), IQVIA (IQV), and Waste Connections (WCN).

How does Medpace compare to Encompass Health?

Medpace (NASDAQ:MEDP) and Encompass Health (NYSE:EHC) are both large-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, profitability, valuation, media sentiment, dividends and risk.

Medpace presently has a consensus price target of $467.08, suggesting a potential upside of 4.47%. Encompass Health has a consensus price target of $142.75, suggesting a potential upside of 34.70%. Given Encompass Health's stronger consensus rating and higher probable upside, analysts plainly believe Encompass Health is more favorable than Medpace.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Medpace	1 Sell rating(s)	10 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.20
Encompass Health	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	3.10

In the previous week, Medpace had 22 more articles in the media than Encompass Health. MarketBeat recorded 31 mentions for Medpace and 9 mentions for Encompass Health. Encompass Health's average media sentiment score of 1.37 beat Medpace's score of 0.28 indicating that Encompass Health is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Medpace	5 Very Positive mention(s)	1 Positive mention(s)	24 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Encompass Health	8 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Medpace has a net margin of 17.19% compared to Encompass Health's net margin of 10.04%. Medpace's return on equity of 120.89% beat Encompass Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Medpace	17.19%	120.89%	24.79%
Encompass Health	10.04%	18.28%	8.27%

Medpace has a beta of 1.19, meaning that its share price is 19% more volatile than the broader market. Comparatively, Encompass Health has a beta of 0.72, meaning that its share price is 28% less volatile than the broader market.

78.0% of Medpace shares are owned by institutional investors. Comparatively, 97.3% of Encompass Health shares are owned by institutional investors. 20.5% of Medpace shares are owned by insiders. Comparatively, 1.8% of Encompass Health shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Encompass Health has higher revenue and earnings than Medpace. Encompass Health is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Medpace	$2.53B	5.05	$451.12M	$15.91	28.10
Encompass Health	$5.94B	1.77	$566.20M	$5.99	17.69

Summary

Medpace beats Encompass Health on 9 of the 17 factors compared between the two stocks.

How does Medpace compare to Elevance Health?

Medpace (NASDAQ:MEDP) and Elevance Health (NYSE:ELV) are both large-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, dividends, analyst recommendations, earnings, institutional ownership, profitability, valuation and risk.

In the previous week, Medpace had 19 more articles in the media than Elevance Health. MarketBeat recorded 31 mentions for Medpace and 12 mentions for Elevance Health. Elevance Health's average media sentiment score of 1.39 beat Medpace's score of 0.28 indicating that Elevance Health is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Medpace	5 Very Positive mention(s)	1 Positive mention(s)	24 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Elevance Health	10 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Medpace has a net margin of 17.19% compared to Elevance Health's net margin of 2.62%. Medpace's return on equity of 120.89% beat Elevance Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Medpace	17.19%	120.89%	24.79%
Elevance Health	2.62%	15.58%	5.57%

Elevance Health has higher revenue and earnings than Medpace. Elevance Health is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Medpace	$2.53B	5.05	$451.12M	$15.91	28.10
Elevance Health	$199.13B	0.43	$5.66B	$23.51	16.78

Medpace currently has a consensus target price of $467.08, suggesting a potential upside of 4.47%. Elevance Health has a consensus target price of $403.11, suggesting a potential upside of 2.21%. Given Medpace's higher probable upside, equities research analysts clearly believe Medpace is more favorable than Elevance Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Medpace	1 Sell rating(s)	10 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.20
Elevance Health	0 Sell rating(s)	9 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.61

78.0% of Medpace shares are held by institutional investors. Comparatively, 89.2% of Elevance Health shares are held by institutional investors. 20.5% of Medpace shares are held by insiders. Comparatively, 0.3% of Elevance Health shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Medpace has a beta of 1.19, indicating that its stock price is 19% more volatile than the broader market. Comparatively, Elevance Health has a beta of 0.66, indicating that its stock price is 34% less volatile than the broader market.

Summary

Medpace beats Elevance Health on 9 of the 16 factors compared between the two stocks.

How does Medpace compare to Hims & Hers Health?

Medpace (NASDAQ:MEDP) and Hims & Hers Health (NYSE:HIMS) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, earnings, media sentiment, risk, dividends and valuation.

Medpace has higher revenue and earnings than Hims & Hers Health. Hims & Hers Health is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Medpace	$2.53B	5.05	$451.12M	$15.91	28.10
Hims & Hers Health	$2.35B	2.58	$128.37M	-$0.09	N/A

78.0% of Medpace shares are held by institutional investors. Comparatively, 63.5% of Hims & Hers Health shares are held by institutional investors. 20.5% of Medpace shares are held by company insiders. Comparatively, 11.8% of Hims & Hers Health shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Medpace had 9 more articles in the media than Hims & Hers Health. MarketBeat recorded 31 mentions for Medpace and 22 mentions for Hims & Hers Health. Hims & Hers Health's average media sentiment score of 0.57 beat Medpace's score of 0.28 indicating that Hims & Hers Health is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Medpace	5 Very Positive mention(s)	1 Positive mention(s)	24 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Hims & Hers Health	9 Very Positive mention(s)	4 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	2 Very Negative mention(s)	Positive

Medpace presently has a consensus price target of $467.08, suggesting a potential upside of 4.47%. Hims & Hers Health has a consensus price target of $28.70, suggesting a potential upside of 9.88%. Given Hims & Hers Health's higher possible upside, analysts plainly believe Hims & Hers Health is more favorable than Medpace.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Medpace	1 Sell rating(s)	10 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.20
Hims & Hers Health	2 Sell rating(s)	11 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.12

Medpace has a beta of 1.19, indicating that its stock price is 19% more volatile than the broader market. Comparatively, Hims & Hers Health has a beta of 2.43, indicating that its stock price is 143% more volatile than the broader market.

Medpace has a net margin of 17.19% compared to Hims & Hers Health's net margin of -0.56%. Medpace's return on equity of 120.89% beat Hims & Hers Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Medpace	17.19%	120.89%	24.79%
Hims & Hers Health	-0.56%	6.10%	1.52%

Summary

Medpace beats Hims & Hers Health on 12 of the 15 factors compared between the two stocks.

How does Medpace compare to IQVIA?

Medpace (NASDAQ:MEDP) and IQVIA (NYSE:IQV) are both large-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, media sentiment, profitability, analyst recommendations, institutional ownership, earnings, dividends and risk.

In the previous week, Medpace had 24 more articles in the media than IQVIA. MarketBeat recorded 31 mentions for Medpace and 7 mentions for IQVIA. IQVIA's average media sentiment score of 0.40 beat Medpace's score of 0.28 indicating that IQVIA is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Medpace	5 Very Positive mention(s)	1 Positive mention(s)	24 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
IQVIA	1 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Medpace has a net margin of 17.19% compared to IQVIA's net margin of 8.33%. Medpace's return on equity of 120.89% beat IQVIA's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Medpace	17.19%	120.89%	24.79%
IQVIA	8.33%	30.50%	6.53%

IQVIA has higher revenue and earnings than Medpace. IQVIA is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Medpace	$2.53B	5.05	$451.12M	$15.91	28.10
IQVIA	$16.31B	1.86	$1.36B	$8.07	22.56

Medpace has a beta of 1.19, indicating that its share price is 19% more volatile than the broader market. Comparatively, IQVIA has a beta of 1.18, indicating that its share price is 18% more volatile than the broader market.

Medpace currently has a consensus target price of $467.08, suggesting a potential upside of 4.47%. IQVIA has a consensus target price of $225.69, suggesting a potential upside of 23.98%. Given IQVIA's stronger consensus rating and higher probable upside, analysts plainly believe IQVIA is more favorable than Medpace.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Medpace	1 Sell rating(s)	10 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.20
IQVIA	0 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	2 Strong Buy rating(s)	3.00

78.0% of Medpace shares are held by institutional investors. Comparatively, 89.6% of IQVIA shares are held by institutional investors. 20.5% of Medpace shares are held by insiders. Comparatively, 1.7% of IQVIA shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Medpace beats IQVIA on 9 of the 17 factors compared between the two stocks.

How does Medpace compare to Waste Connections?

Medpace (NASDAQ:MEDP) and Waste Connections (NYSE:WCN) are both large-cap business services companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, profitability, analyst recommendations, institutional ownership, earnings, valuation, risk and media sentiment.

In the previous week, Medpace had 24 more articles in the media than Waste Connections. MarketBeat recorded 31 mentions for Medpace and 7 mentions for Waste Connections. Waste Connections' average media sentiment score of 1.30 beat Medpace's score of 0.28 indicating that Waste Connections is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Medpace	5 Very Positive mention(s)	1 Positive mention(s)	24 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Waste Connections	6 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

78.0% of Medpace shares are held by institutional investors. Comparatively, 86.1% of Waste Connections shares are held by institutional investors. 20.5% of Medpace shares are held by company insiders. Comparatively, 0.3% of Waste Connections shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Medpace presently has a consensus price target of $467.08, suggesting a potential upside of 4.47%. Waste Connections has a consensus price target of $203.35, suggesting a potential upside of 36.36%. Given Waste Connections' stronger consensus rating and higher probable upside, analysts clearly believe Waste Connections is more favorable than Medpace.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Medpace	1 Sell rating(s)	10 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.20
Waste Connections	0 Sell rating(s)	4 Hold rating(s)	14 Buy rating(s)	4 Strong Buy rating(s)	3.00

Waste Connections has higher revenue and earnings than Medpace. Medpace is trading at a lower price-to-earnings ratio than Waste Connections, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Medpace	$2.53B	5.05	$451.12M	$15.91	28.10
Waste Connections	$9.47B	4.02	$1.08B	$4.10	36.37

Medpace has a net margin of 17.19% compared to Waste Connections' net margin of 10.97%. Medpace's return on equity of 120.89% beat Waste Connections' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Medpace	17.19%	120.89%	24.79%
Waste Connections	10.97%	16.49%	6.45%

Medpace has a beta of 1.19, indicating that its stock price is 19% more volatile than the broader market. Comparatively, Waste Connections has a beta of 0.55, indicating that its stock price is 45% less volatile than the broader market.

Summary

Waste Connections beats Medpace on 9 of the 17 factors compared between the two stocks.

Get Medpace News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MEDP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MEDP vs. The Competition

Export

Metric	Medpace	Medical Services Industry	Medical Sector	NASDAQ Exchange
Market Cap	$12.77B	$8.52B	$5.82B	$12.56B
Dividend Yield	N/A	1.76%	2.69%	5.31%
P/E Ratio	28.10	21.99	21.63	26.27
Price / Sales	5.05	26.54	626.55	142.41
Price / Cash	26.28	90.46	43.22	56.84
Price / Book	21.34	5.91	10.55	7.30
Net Income	$451.12M	$183.47M	$3.56B	$337.27M
7 Day Performance	3.31%	2.88%	2.85%	3.58%
1 Month Performance	6.80%	10.54%	4.59%	5.71%
1 Year Performance	50.82%	5.69%	37.62%	39.70%

Medpace Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MEDP Medpace	2.2941 of 5 stars	$447.11 -0.2%	$467.08 +4.5%	+50.8%	$12.77B	$2.53B	28.10	6,200	Trending News
EHC Encompass Health	4.6222 of 5 stars	$105.04 +0.1%	$145.29 +38.3%	-12.4%	$10.41B	$5.94B	17.54	42,000	Positive News Analyst Forecast
ELV Elevance Health	4.3986 of 5 stars	$394.41 -0.1%	$399.32 +1.2%	+2.7%	$85.71B	$199.13B	16.78	97,100	Positive News Analyst Forecast
HIMS Hims & Hers Health	3.0961 of 5 stars	$23.71 -0.2%	$28.90 +21.9%	-54.0%	$5.41B	$2.35B	N/A	2,442	Analyst Forecast Insider Trade
IQV IQVIA	4.3113 of 5 stars	$168.28 +0.2%	$225.69 +34.1%	+29.9%	$28.02B	$16.31B	20.85	93,000

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MEDP) was last updated on 5/31/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Medpace (MEDP) Competitors

MEDP vs. EHC, ELV, HIMS, IQV, and WCN

How does Medpace compare to Encompass Health?

Summary

How does Medpace compare to Elevance Health?

Summary

How does Medpace compare to Hims & Hers Health?

Summary

How does Medpace compare to IQVIA?

Summary

How does Medpace compare to Waste Connections?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MEDP vs. The Competition

Medpace Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Medpace (MEDP) Competitors

MEDP vs. EHC, ELV, HIMS, IQV, and WCN

How does Medpace compare to Encompass Health?

Do analysts rate MEDP or EHC?

Does the media favor MEDP or EHC?

Is MEDP or EHC more profitable?

Which has more volatility & risk, MEDP or EHC?

Do insiders & institutionals have more ownership in MEDP or EHC?

Which has preferable earnings & valuation, MEDP or EHC?

Summary

How does Medpace compare to Elevance Health?

Does the media refer more to MEDP or ELV?

Is MEDP or ELV more profitable?

Which has stronger valuation & earnings, MEDP or ELV?

Do analysts rate MEDP or ELV?

Do institutionals and insiders have more ownership in MEDP or ELV?

Which has more volatility and risk, MEDP or ELV?

Summary

How does Medpace compare to Hims & Hers Health?

Which has better earnings and valuation, MEDP or HIMS?

Do institutionals & insiders have more ownership in MEDP or HIMS?

Does the media refer more to MEDP or HIMS?

Do analysts rate MEDP or HIMS?

Which has more risk & volatility, MEDP or HIMS?

Is MEDP or HIMS more profitable?

Summary

How does Medpace compare to IQVIA?

Does the media refer more to MEDP or IQV?

Is MEDP or IQV more profitable?

Which has preferable valuation and earnings, MEDP or IQV?

Which has more volatility & risk, MEDP or IQV?

Do analysts rate MEDP or IQV?

Do insiders & institutionals have more ownership in MEDP or IQV?

Summary

How does Medpace compare to Waste Connections?

Does the media refer more to MEDP or WCN?

Do insiders and institutionals have more ownership in MEDP or WCN?

Do analysts rate MEDP or WCN?

Which has stronger earnings & valuation, MEDP or WCN?

Is MEDP or WCN more profitable?

Which has more volatility and risk, MEDP or WCN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MEDP vs. The Competition

Medpace Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools